<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391053</url>
  </required_header>
  <id_info>
    <org_study_id>FIM05</org_study_id>
    <nct_id>NCT00391053</nct_id>
  </id_info>
  <brief_title>Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly</brief_title>
  <official_title>Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compared to young adults, the elderly mount a lower antibody response to vaccination. Thus,
      improvement of the immune response to influenza vaccination in this age group, which is at
      higher risk for influenza-related morbidity and mortality, represents an important unmet
      need.

      Primary Objectives:

      Immunogenicity:

        -  To demonstrate lot consistency of the Fluzone High Dose (Fluzone HD) manufacturing
           process through evaluation of the immune responses elicited by three different lots.

        -  To demonstrate the superiority of Fluzone HD vaccine compared to standard-dose Fluzone®
           vaccine.

      Secondary Objectives:

      Immunogenicity:

        -  To describe the seroprotection of Fluzone HD compared to that of standard dose Fluzone®
           vaccine.

      Safety:

        -  To describe the safety profile of Fluzone HD, in terms of solicited -, unsolicited
           adverse and serious adverse events post-vaccination.

        -  To describe clinical information on some additional defined criteria during the six
           months following vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines.</measure>
    <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
    <description>Antibodies against each of three Influenza antigens (virus) in Fluzone® High-Dose and Standard Fluzone® vaccines (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) were determined by the Hemagglutination inhibition assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion Post-vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</measure>
    <time_frame>Day 28 Post-vaccination</time_frame>
    <description>Seroconversion was defined as a Hemagglutination Inhibition Antibody Titers of Titer ≥40 (1/dil) on Day 28 if pre-vaccination (Day 0) titer &lt;10 (1/dil); or a four-fold increase of titer on Day 28, if pre-vaccination (Day 0) titer is ≥10 (1/dil) for each of the three Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroprotection Pre- and Post-Vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</measure>
    <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
    <description>Seroprotection was defined as a Hemagglutination Inhibition Titers of at least 40 (≥ 1:40) for each of the Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) pre- or post-vaccination with Fluzone® High-Dose or Standard Fluzone® vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Solicited Injection Site and Systemic Reactions After Fluzone® High-Dose or Standard Fluzone® Vaccination</measure>
    <time_frame>Day 0 to Day 7 Post-vaccination</time_frame>
    <description>The occurrence, time to onset, number of days of occurrence, and severity of solicited injection site reactions: Injection Site Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia were collected.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3851</enrollment>
  <condition>Orthomyxoviridae Infection</condition>
  <condition>Influenza</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the Standard Fluzone® vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Inactivated, Split-Virion Influenza Vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Study Group 1</arm_group_label>
    <other_name>Fluzone® High-Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Inactivated, Split-Virion Influenza Vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Study Group 2</arm_group_label>
    <other_name>Fluzone® High-Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Inactivated, Split-Virion Influenza Vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Study Group 3</arm_group_label>
    <other_name>Fluzone® High-Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated, Split-Virion Influenza Vaccine</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Fluzone® 2006-2007 formulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 65 years on the day of vaccination.

          -  Informed consent form signed.

          -  Medically stable. (Subjects may have underlying chronic conditions such as
             hypertension, diabetes, ischemic heart disease, or hypothyroidism, as long as their
             symptoms/signs are controlled. If they are on medication for a condition, the
             medication dose must have been stable for at least 3 weeks preceding vaccination.)

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components,
             or a history of a life-threatening reaction to the standard-dose Fluzone® vaccine or a
             vaccine containing any of the same substances.

          -  Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such
             as anti-cancer chemotherapy or radiation therapy within the preceding six months.

          -  Systemic corticosteroid therapy, as follows:

        Continuous use with a dosage equivalent to &gt; 15 mg/day of oral prednisone for 90 days
        preceding vaccination.

        Sporadic use with a dosage equivalent to &gt; 40 mg/day of oral prednisone for &gt; 14
        consecutive days in the 90 days preceding vaccination.

        Note:Use of topical or inhalant corticosteroids is acceptable.

          -  Neoplastic disease or any hematologic malignancy (except localized skin or prostate
             cancer that is stable at the time of vaccination in the absence of therapy, as well as
             subjects who have a history of neoplastic disease and who have been disease-free for ≥
             5 years).

          -  Current alcohol abuse or drug addiction that in the opinion of the investigator may
             interfere with the subject's ability to comply with trial procedures.

          -  Receipt of blood or blood-derived products in the past three months.

          -  Participation in a trial of a high-dose influenza vaccine in the past 12 months.

          -  Receipt of influenza vaccine in the past six months.

          -  Receipt of any other vaccine in the past four weeks.

          -  Planned receipt of any other vaccine in the four weeks following the trial
             vaccination.

          -  Participation in another clinical trial in the past four weeks.

          -  Planned participation in another clinical trial during the present trial period.

        Note:Concomitant participation in an observational trial (not involving drugs, vaccines, or
        medical devices) is acceptable.

          -  Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination.

          -  History of Guillain-Barré syndrome.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  An acute febrile illness (oral temperature ≥ 99.5ºF [≥ 37.5ºC]) within 24 hours prior
             to vaccination. If this contraindication exists, vaccination will be deferred until
             the participant has been afebrile for at least 24 hours.

          -  Signs and symptoms of an acute infectious respiratory illness. If this exists,
             vaccination will be deferred until the symptoms resolve.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stratford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downington</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <results_reference>
    <citation>Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009 Jul 15;200(2):172-80. doi: 10.1086/599790.</citation>
    <PMID>19508159</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <results_first_submitted>January 14, 2010</results_first_submitted>
  <results_first_submitted_qc>March 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2010</results_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 09 October 2006 to 21 December 2006 at 30 US sites.</recruitment_details>
      <pre_assignment_details>A total of 3851 participants who met the inclusion and exclusion criteria were randomized and vaccinated. The vaccine received by 14 participants could not be verified, they were excluded from all analyses except immunogenicity analysis. 4 participants that started the study, but had no post-vaccination assessment were also excluded from analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
        </group>
        <group group_id="P2">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
        </group>
        <group group_id="P3">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
        </group>
        <group group_id="P4">
          <title>Active Comparator (Standard Fluzone®)</title>
          <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="857"/>
                <participants group_id="P2" count="848"/>
                <participants group_id="P3" count="870"/>
                <participants group_id="P4" count="1262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="848"/>
                <participants group_id="P2" count="847"/>
                <participants group_id="P3" count="868"/>
                <participants group_id="P4" count="1252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious Adverse Events</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
        </group>
        <group group_id="B2">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
        </group>
        <group group_id="B3">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
          <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
        </group>
        <group group_id="B4">
          <title>Active Comparator (Standard Fluzone®)</title>
          <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="855"/>
            <count group_id="B2" value="848"/>
            <count group_id="B3" value="870"/>
            <count group_id="B4" value="1260"/>
            <count group_id="B5" value="3833"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="855"/>
                    <measurement group_id="B2" value="848"/>
                    <measurement group_id="B3" value="870"/>
                    <measurement group_id="B4" value="1260"/>
                    <measurement group_id="B5" value="3833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" spread="6.15"/>
                    <measurement group_id="B2" value="72.9" spread="6.20"/>
                    <measurement group_id="B3" value="72.9" spread="6.17"/>
                    <measurement group_id="B4" value="72.9" spread="5.99"/>
                    <measurement group_id="B5" value="72.9" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="445"/>
                    <measurement group_id="B4" value="688"/>
                    <measurement group_id="B5" value="2008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="418"/>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="425"/>
                    <measurement group_id="B4" value="572"/>
                    <measurement group_id="B5" value="1825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="855"/>
                    <measurement group_id="B2" value="848"/>
                    <measurement group_id="B3" value="870"/>
                    <measurement group_id="B4" value="1260"/>
                    <measurement group_id="B5" value="3833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines.</title>
        <description>Antibodies against each of three Influenza antigens (virus) in Fluzone® High-Dose and Standard Fluzone® vaccines (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) were determined by the Hemagglutination inhibition assay method.</description>
        <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
        <population>The geometric mean titers was assessed in the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
          </group>
          <group group_id="O3">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
          </group>
          <group group_id="O4">
            <title>Active Comparator (Standard Fluzone®)</title>
            <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers Pre- and Post-vaccination With Fluzone® High Dose or Standard Fluzone® Vaccines.</title>
          <description>Antibodies against each of three Influenza antigens (virus) in Fluzone® High-Dose and Standard Fluzone® vaccines (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) were determined by the Hemagglutination inhibition assay method.</description>
          <population>The geometric mean titers was assessed in the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="854"/>
                <count group_id="O2" value="861"/>
                <count group_id="O3" value="861"/>
                <count group_id="O4" value="1275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 New Caledonia Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.25" lower_limit="26.37" upper_limit="30.26"/>
                    <measurement group_id="O2" value="29.41" lower_limit="27.39" upper_limit="31.57"/>
                    <measurement group_id="O3" value="27.86" lower_limit="25.94" upper_limit="29.93"/>
                    <measurement group_id="O4" value="29.36" lower_limit="27.72" upper_limit="31.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 New Caledonia Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.77" lower_limit="105.64" upper_limit="120.37"/>
                    <measurement group_id="O2" value="114.63" lower_limit="107.18" upper_limit="122.61"/>
                    <measurement group_id="O3" value="120.02" lower_limit="112.12" upper_limit="128.48"/>
                    <measurement group_id="O4" value="67.29" lower_limit="63.65" upper_limit="71.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Wisconsin Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.53" lower_limit="67.29" upper_limit="82.55"/>
                    <measurement group_id="O2" value="77.3" lower_limit="69.5" upper_limit="85.97"/>
                    <measurement group_id="O3" value="72.07" lower_limit="65.12" upper_limit="79.77"/>
                    <measurement group_id="O4" value="74.74" lower_limit="68.64" upper_limit="81.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Wisconsin Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595.03" lower_limit="552.8" upper_limit="640.49"/>
                    <measurement group_id="O2" value="628.54" lower_limit="583.21" upper_limit="677.4"/>
                    <measurement group_id="O3" value="603.59" lower_limit="561.33" upper_limit="649.03"/>
                    <measurement group_id="O4" value="332.46" lower_limit="310.44" upper_limit="356.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.24" lower_limit="17.98" upper_limit="20.58"/>
                    <measurement group_id="O2" value="18.96" lower_limit="17.71" upper_limit="20.29"/>
                    <measurement group_id="O3" value="19.78" lower_limit="18.49" upper_limit="21.16"/>
                    <measurement group_id="O4" value="18.96" lower_limit="17.93" upper_limit="20.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.98" lower_limit="64.77" upper_limit="73.47"/>
                    <measurement group_id="O2" value="69.26" lower_limit="64.99" upper_limit="73.81"/>
                    <measurement group_id="O3" value="68.93" lower_limit="64.81" upper_limit="73.3"/>
                    <measurement group_id="O4" value="52.34" lower_limit="49.48" upper_limit="55.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion Post-vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</title>
        <description>Seroconversion was defined as a Hemagglutination Inhibition Antibody Titers of Titer ≥40 (1/dil) on Day 28 if pre-vaccination (Day 0) titer &lt;10 (1/dil); or a four-fold increase of titer on Day 28, if pre-vaccination (Day 0) titer is ≥10 (1/dil) for each of the three Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia).</description>
        <time_frame>Day 28 Post-vaccination</time_frame>
        <population>The immunogenicity analysis was performed on the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
          </group>
          <group group_id="O3">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
          </group>
          <group group_id="O4">
            <title>Active Comparator (Standard Fluzone®)</title>
            <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion Post-vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</title>
          <description>Seroconversion was defined as a Hemagglutination Inhibition Antibody Titers of Titer ≥40 (1/dil) on Day 28 if pre-vaccination (Day 0) titer &lt;10 (1/dil); or a four-fold increase of titer on Day 28, if pre-vaccination (Day 0) titer is ≥10 (1/dil) for each of the three Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia).</description>
          <population>The immunogenicity analysis was performed on the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="854"/>
                <count group_id="O2" value="861"/>
                <count group_id="O3" value="861"/>
                <count group_id="O4" value="1275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 New Caledonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroprotection Pre- and Post-Vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</title>
        <description>Seroprotection was defined as a Hemagglutination Inhibition Titers of at least 40 (≥ 1:40) for each of the Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) pre- or post-vaccination with Fluzone® High-Dose or Standard Fluzone® vaccines.</description>
        <time_frame>Day 0 and Day 28 Post-vaccination</time_frame>
        <population>The immunogenicity analysis was performed on the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
          </group>
          <group group_id="O3">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
          </group>
          <group group_id="O4">
            <title>Active Comparator (Standard Fluzone®)</title>
            <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection Pre- and Post-Vaccination With Fluzone® High-Dose or Standard Fluzone® Vaccines.</title>
          <description>Seroprotection was defined as a Hemagglutination Inhibition Titers of at least 40 (≥ 1:40) for each of the Influenza vaccine antigens (A/H1N1 New-Caledonia; A/H3N2 Wisconsin; and B Malaysia) pre- or post-vaccination with Fluzone® High-Dose or Standard Fluzone® vaccines.</description>
          <population>The immunogenicity analysis was performed on the Full Analysis Set according to the vaccine the subjects were randomized to receive. A total of 3851 participants were included in this analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="854"/>
                <count group_id="O2" value="861"/>
                <count group_id="O3" value="861"/>
                <count group_id="O4" value="1275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 New Caledonia Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 New Caledonia Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Wisconsin Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Wisconsin Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia Post-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Solicited Injection Site and Systemic Reactions After Fluzone® High-Dose or Standard Fluzone® Vaccination</title>
        <description>The occurrence, time to onset, number of days of occurrence, and severity of solicited injection site reactions: Injection Site Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia were collected.</description>
        <time_frame>Day 0 to Day 7 Post-vaccination</time_frame>
        <population>The safety analysis was performed on the Full Analysis Set according to the participants who actually received a vaccine, whether or not the subject received the assigned vaccine. A total of 3,833 participants were included in the analysis set for the evaluation of all safety.</population>
        <group_list>
          <group group_id="O1">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 1</description>
          </group>
          <group group_id="O2">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 2</description>
          </group>
          <group group_id="O3">
            <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
            <description>Participants aged 65 years or older at enrollment, treated with high-dose trivalent inactivated influenza vaccine (Fluzone HD) 2006-2007 formulation, Lot 3</description>
          </group>
          <group group_id="O4">
            <title>Active Comparator (Standard Fluzone®)</title>
            <description>Participants aged 65 years or older at enrollment, treated with standard Fluzone® vaccine 2006-2007 formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Solicited Injection Site and Systemic Reactions After Fluzone® High-Dose or Standard Fluzone® Vaccination</title>
          <description>The occurrence, time to onset, number of days of occurrence, and severity of solicited injection site reactions: Injection Site Pain, Erythema, and Swelling; Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia were collected.</description>
          <population>The safety analysis was performed on the Full Analysis Set according to the participants who actually received a vaccine, whether or not the subject received the assigned vaccine. A total of 3,833 participants were included in the analysis set for the evaluation of all safety.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="855"/>
                <count group_id="O2" value="848"/>
                <count group_id="O3" value="870"/>
                <count group_id="O4" value="1260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Injection Site Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Erythema (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Systemic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (&gt;102.2 ºF or &gt;39.0 ºC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (Prevents Daily Activities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from day of vaccination (Day 0) for 6 months post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1</title>
        </group>
        <group group_id="E2">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2</title>
        </group>
        <group group_id="E3">
          <title>High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3</title>
        </group>
        <group group_id="E4">
          <title>Standad Dose Inactivated, Split-Virion Influenza Vaccine</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="855"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="870"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="855"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="870"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Implant site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="855"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="848"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="870"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pacemaker complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Helicobacter pylori identification test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Sinus cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="870"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="855"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="848"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="455" subjects_at_risk="855"/>
                <counts group_id="E2" subjects_affected="454" subjects_at_risk="848"/>
                <counts group_id="E3" subjects_affected="449" subjects_at_risk="870"/>
                <counts group_id="E4" subjects_affected="544" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="136" subjects_affected="136" subjects_at_risk="855"/>
                <counts group_id="E2" events="125" subjects_affected="125" subjects_at_risk="848"/>
                <counts group_id="E3" events="123" subjects_affected="123" subjects_at_risk="870"/>
                <counts group_id="E4" events="136" subjects_affected="136" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="295" subjects_affected="295" subjects_at_risk="855"/>
                <counts group_id="E2" events="292" subjects_affected="292" subjects_at_risk="848"/>
                <counts group_id="E3" events="328" subjects_affected="328" subjects_at_risk="870"/>
                <counts group_id="E4" events="306" subjects_affected="306" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="855"/>
                <counts group_id="E2" events="76" subjects_affected="76" subjects_at_risk="848"/>
                <counts group_id="E3" events="75" subjects_affected="75" subjects_at_risk="870"/>
                <counts group_id="E4" events="73" subjects_affected="73" subjects_at_risk="1260"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="173" subjects_affected="173" subjects_at_risk="855"/>
                <counts group_id="E2" events="150" subjects_affected="150" subjects_at_risk="848"/>
                <counts group_id="E3" events="139" subjects_affected="139" subjects_at_risk="870"/>
                <counts group_id="E4" events="176" subjects_affected="176" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="197" subjects_affected="197" subjects_at_risk="855"/>
                <counts group_id="E2" events="175" subjects_affected="175" subjects_at_risk="848"/>
                <counts group_id="E3" events="178" subjects_affected="178" subjects_at_risk="870"/>
                <counts group_id="E4" events="230" subjects_affected="230" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="146" subjects_affected="146" subjects_at_risk="855"/>
                <counts group_id="E2" events="138" subjects_affected="138" subjects_at_risk="848"/>
                <counts group_id="E3" events="147" subjects_affected="147" subjects_at_risk="870"/>
                <counts group_id="E4" events="182" subjects_affected="182" subjects_at_risk="1260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

